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Placental insufficiency can cause fetal growth restriction and stillbirth. There are no reliable
screening tests for placental insufficiency, especially near-term gestation when the risk of
stillbirth rises. Here we show a strong association between low circulating plasma serine
peptidase inhibitor Kunitz type-1 (SPINT1) concentrations at 36 weeks’ gestation and low
birthweight, an indicator of placental insufficiency. We generate a 4-tier risk model based on
SPINT1 concentrations, where the highest risk tier has approximately a 2-5 fold risk of
birthing neonates with birthweights under the 3rd, 5th, 10th and 20th centiles, whereas the
lowest risk tier has a 0-0.3 fold risk. Low SPINT1 is associated with antenatal ultrasound and
neonatal anthropomorphic indicators of placental insufficiency. We validate the association
between low circulating SPINT1 and placental insufficiency in two other cohorts. Low cir-
culating SPINT1 is a marker of placental insufficiency and may identify pregnancies with an
elevated risk of stillbirth.
https://doi.org/10.1038/s41467-020-16346-x OPEN
1 Translational Obstetrics Group, The Department of Obstetrics and Gynaecology, Mercy Hospital for Women, University of Melbourne, Heidelberg 3084
Victoria, Australia. 2Mercy Perinatal, Mercy Hospital for Women, Heidelberg 3084 Victoria, Australia. 3 Foresight Health, Adelaide, 169 Fullarton Rd.,
Dulwich 5065 South Australia, Australia. 4 University of Manchester, Manchester Academic Health Science Centre, St Mary’s Hospital, Manchester M13
OJH, UK. 5 Pathology Department, Austin Health, Heidelberg 3084 Victoria, Australia. 6 Centre for Trophoblast Research, Department of Physiology,
Development and Neuroscience, University of Cambridge, Cambridge CB2 3EG, UK. 7These authors contributed equally: Tu’uhevaha J. Kaitu’u-Lino,
Teresa M. MacDonald, Susan P. Walker, Stephen Tong. ✉email: t.klino@unimelb.edu.au; stong@unimelb.edu.au
NATURE COMMUNICATIONS |         (2020) 11:2411 | https://doi.org/10.1038/s41467-020-16346-x | www.nature.com/naturecommunications 1
12
34
56
78
9
0
()
:,;
P lacental insufficiency and fetal growth restriction arise whenthe placenta is functioning poorly and is the largest singlecontributor to the risk of stillbirth. If identified antenatally,
close fetal surveillance and timed birth may decrease the risk of
stillbirth1.
There is avid interest in finding better ways to detect placental
insufficiency, especially among pregnancies around term gesta-
tion, because the risk of stillbirth rises sharply from around
38 weeks of pregnancy1–3 and inducing labor is a very safe
option4,5.
The presence of placental insufficiency leads to a cascade of
pathological events as the fetus tries to cope with poor placental
function6. These include a slowing in growth resulting in fetal
growth restriction, and low birth and placental weights. It can
also lead to increased blood flow resistance in the uterine artery
(maternal) and umbilical (placental) arteries. Decreased oxygen
availability can cause the fetus to divert blood from its periphery
to the brain. These blood flow changes can be measured by
Doppler ultrasound of the uterine, umbilical or fetal middle
cerebral artery, respectively.
When faced with decreased nutrient supply from a poorly
functioning placenta, fetuses can also exhaust their energy
reserves in utero leading to decreased fat stores. This can be
identified postnatally by air displacement plethysmography of
neonatal body composition measurements done soon after birth.
Despite these associations, antenatal tests to identify preg-
nancies affected by placental insufficiency perform modestly,
especially at near-term gestations. The current clinical approach
is to try to detect small for gestational age fetuses (SGA, fetal
weight <10th centile) given they are associated with a 3–4 fold
increased risk of stillbirth1–3. To detect SGA fetuses, it is almost
universal antenatal practice to estimate the uterine size (sym-
physial fundal height) at clinic visits by placing a tape measure on
the patient’s abdomen, and selectively send those with small
measurements for an ultrasound scan to estimate the fetal weight.
Unfortunately, this time-honored practice of selective ultrasound
scanning of women with a clinical suspicion of an SGA fetus only
detects 20–30% (sensitivity) of all cases7–9.
Furthermore, SGA itself may not be a good indicator of placental
insufficiency. Many SGA fetuses are in fact constitutionally small,
that is, healthy fetuses without placental insufficiency and a low
baseline stillbirth risk10. The proportion of fetuses that are genu-
inely growth restricted from placental insufficiency (rather than
being constitutionally small) rises sharply with decreasing fetal
weight centiles below the 10th. This is reflected by an exponential
increase in the incidence of stillbirth with linear step-wise decreases
in birthweight centiles below the 10th. Thus, the risk of stillbirth is
particularly high for fetuses with a weight <3rd centile.
Other antenatal options to identify placental insufficiency
include performing ultrasounds to identify fetuses with increased
umbilical artery Doppler resistance, or increased middle cerebral
artery Doppler blood flow velocities. While these methods are still
being evaluated, none appear likely to be good diagnostic markers
of placental insufficiency, especially near term11–13, probably
because these adaptive circulatory responses do not occur with
sufficient reliability to form the basis of a sensitive clinical test.
Thus, there is a clinical need to find better tests for placental
insufficiency to decrease rates of stillbirth. Therefore, we set out
to identify and validate new circulating markers of placental
insufficiency. We prospectively collected plasma from 2003
women at 36 weeks’ gestation and divided the samples to discover
(cohort 1, n= 1001) then validate (cohort 2, n= 1002) bio-
markers. By screening 22 proteins in cohort 1 we identify a strong
association between low circulating plasma serine peptidase
inhibitor, Kunitz type-1 (SPINT1) concentrations and low
birthweight (<10th centile), a marker of placental insufficiency in
utero. We validate this association in cohort 2 and generate a 4-
tier risk model based on SPINT1 concentrations. We show
SPINT1 is associated with several ultrasound and neonatal
anthropomorphic parameters that are known to be associated
with placental insufficiency. We also show SPINT1 expression is
decreased in placentas from cases of preterm fetal growth
restriction (a severe form of placental insufficiency) and from an
animal model of fetal growth restriction. We validate the asso-
ciation between low circulating SPINT1 concentrations in a
cohort from the United Kingdom and in women with preterm
fetal growth restriction. Our work identifies low circulating
SPINT1 as a marker of placental insufficiency.
Results
Screening and validation of new biomarkers. We performed the
Fetal Longitudinal Assessment of Growth study (FLAG) a pro-
spective collection of plasma samples at 28 and 36 weeks of
pregnancy. To identify biomarkers of placental insufficiency
relevant to term gestation we focused on plasma samples collected
around 36 weeks’ gestation. We divided the cohort approximately
in half to discover, then validate markers: the first 1001 (cohort 1)
and the second 1002 consecutively recruited participants (cohort
2). The clinical characteristics of both cohorts are shown in
Supplementary Tables 1 and 2.
To identify biomarkers of placental insufficiency we measured
plasma concentrations of 22 proteins that we identified using
bioinformatics as highly expressed in the placenta relative to other
tissues in the body, especially on the surface of the placenta. We
measured these in samples from a nested case–control subset of 105
cases of SGA (small for gestational age, or birthweight <10th
centile) and 210 non-SGA controls selected from cohort 1. While
the function of many of these proteins remain poorly understood,
we postulated that being deliberately expressed at such high levels in
the placenta, most will play important biological roles. This could
then mean that the expression of some of them will be perturbed in
the presence of placental insufficiency.
Circulating concentrations of 4 of the 22 proteins we screened
were significantly altered with SGA compared with non-SGA
controls: SPINT1, syndecan-1, growth differentiation factor-15
(GDF15), and death-associated protein kinase-1 (DAPK1,
Supplementary Fig. 1). Thirteen were unchanged (Supplementary
Fig. 2) and five were undetectable (listed in Supplementary
Table 3). We re-assayed SPINT1 (Fig. 1a, b), syndecan-1, GDF-15
(Supplementary Fig. 3a–d) and DAPK-1 in samples from cohort
1 (n= 997 available) which, unlike the case–control study, brings
the prevalence of SGA to that of the entire population. We
confirmed that circulating concentrations of all of them except
DAPK-1 (not shown) remained significantly changed.
We then validated these findings by measuring circulating
SPINT1, syndecan-1 and GDF-15 at 36 weeks’ gestation in cohort
2, an independent cohort from that we used to first identify their
associations with SGA. All three analytes were significantly
deranged in pregnancies destined to birth an SGA neonate
(Fig. 1c, d shows SPINT1 in cohort 2, and Supplementary Fig.
3e–h shows GDF-15 and syndecan-1). In cohort 2 circulating
placental growth factor (PIGF) was also significantly changed
with SGA (Fig. 1e, f), while soluble fms-like tyrosine kinase 1
(sFlt1) concentrations were not (Supplementary Fig. 3i, j). A
statistical comparison of the ROC curves showed the AUC for
SPINT1 is significantly greater than PlGF (p= 0.03, Fig. 1g).
Thus, of all these analytes, SPINT1 appeared to have the strongest
association with SGA.
Circulating SPINT1 concentrations were already significantly
decreased at 28 weeks among those destined to birth an
SGA neonate (data derived from case-cohort set selected from
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cohort 1, see Fig. 1h). For many cases of SGA where SPINT1
concentrations were low at 28 weeks’ gestation, levels remained
depressed at 36 weeks’ gestation (Fig. 1i) suggesting levels may be
low for months prior to the birth of an SGA infant at term
gestation.
Developing and validating tests to predict low birthweight.
Circulating SPINT1 concentrations at 36 weeks’ gestation in
cohort 2 (our independent validation cohort where SPINT1 reads
were available for n= 998) identified a group with an elevated
risk of birthing low birthweight infants (Table 1). Of note, 37.9%
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who screened positive had a birthweight centile <20th. This may
be clinically significant given a fetal weight <20th centile still has a
stillbirth risk twofold that of fetuses at around 50–90th cen-
tiles3,14. In contrast, the diagnostic performance of PIGF was
more modest (Supplementary Table 4). Given significant differ-
ences in some maternal parameters between the groups (such as
age, smoking, parity and body mass index), we also examined the
predictive ability of SPINT1 at 36 weeks’ gestation to detect
fetuses <10th, <5th, and <3rd centiles after adjusting for these
maternal factors. This did not significantly alter the performance
of circulating SPINT1 (Supplementary Table 5). SPINT1 also
performed better as a diagnostic test compared with combining
clinical characteristics that are associated with an increased risk of
birthing a low birthweight neonate (Supplementary Table 5).
The a priori intent of the FLAG study was to try to find a
combination of markers providing the best diagnostic perfor-
mance to detect fetal growth restriction. However, using logistic
regression approaches we were unable to identify a multi-marker
predictive test that added to the test performance of SPINT1
alone to identify neonates destined to be born <10th, <5th and
<3rd birthweight centiles (Supplementary Tables 6, 7, 8
respectively). Given it has been previously proposed that sFlt1
and PIGF expressed as a ratio may be able to predict the presence
of placental insufficiency15,16, we also assessed the predictive
performance of sFlt1/PlGF (Supplementary Table 9). Expressing
sFlt1 and PlGF as a ratio produced screening tests that performed
more poorly compared with either PlGF alone (Supplementary
Table 4) or to SPINT1 (Table 1).
Using cohort 2, we developed a 4-tier risk model based on
different SPINT1 MoM concentrations (Table 2). Those among
the highest tier of risk (7.1% of cohort 2 with the lowest SPINT1
MoMs) had 14.1%, 19.7%, 28.2% and 46.5% risk of delivering
neonates with birthweights <3rd, <5th, <10th and <20th centiles
respectively. In contrast, those within the lowest tier of risk (9.1%
of cohort 1) had 0.0%, 1.1%, 1.1% and 6.6% risk of birthing
neonates at <3rd, <5th, <10th and <20th centiles. In this 4-tier
risk model, rates of birthing infants at these birthweight centiles
compared with the baseline population prevalence in the cohorts
were elevated by 2–5 fold if circulating SPINT1 concentrations
were within tier 1 (highest risk), similar to the background
population prevalence for tier 2, around half of the population
prevalence in tier 3, and were very low in tier 4.
SPINT1 and clinical markers of placental insufficiency. We
next investigated the association between SPINT1 and various
clinical parameters of placental insufficiency. We did this by
examining data from across both cohorts 1 and 2 (after com-
pleting our discovery and validation studies).
We performed ultrasounds at 36 weeks’ gestation in a
subgroup of 347 nulliparous women (spread across cohorts 1
and 2), followed by air displacement plethysmography (PEA-
POD) on the neonates after birth. SPINT1 was negatively
correlated with the uterine artery (Fig. 2a) but not umbilical
artery Doppler velocity (Supplementary Fig. 4a) measured at
36 weeks’ gestation and was positively correlated with neonatal
lean mass (Fig. 2b) but not fat mass (Supplementary Figure 4b,c).
SPINT1 was also strongly correlated with placental weight
(Fig. 2c). In contrast, the associations between PIGF and these
indicators of placental insufficiency were either not significant, or
more modest (Supplementary Fig. 5).
We also found a step-wise decrease in plasma SPINT1
concentrations between controls (>10th centile) and decreasing
birthweight centiles (Fig. 2d). Plasma SPINT1 concentrations at
36 weeks were continuously correlated across all birthweight
centiles (Fig. 2e, available data from cohorts 1 and 2 were
combined).
Validating SPINT1 in an independent high-risk cohort. We
next sought to validate the association between low circulating
SPINT1 concentrations and placental insufficiency in an inde-
pendent cohort. We measured plasma SPINT1 concentrations
obtained from women at 24–34 weeks’ gestation presenting to the
Manchester Antenatal Vascular Service (MAViS clinic, clinical
characteristics shown in Supplementary Table 10). In contrast to
the low-risk cohort recruited in the FLAG study, women referred
to this clinic were those with current hypertension, or a hyper-
tensive disorder in a previous pregnancy. They were high-risk
pregnancies because pregnant women with pre-existing vascular
disease are at significantly increased risk of preeclampsia, SGA or
fetal growth restriction.
Circulating SPINT1 concentrations in this cohort were
significantly depressed among 83 women who birthed an SGA
neonate (n= 83) compared with 208 who did not (Fig. 3a, b) and
levels were further reduced among those who birthed neonates
<5th birthweight centile (Fig. 3c). Similar to findings made in the
FLAG cohort (Fig. 2e), SPINT1 concentrations were continuously
correlated with birthweight centiles (Fig. 3d) and the uterine
artery Doppler velocities measurements taken at the time of blood
sampling (Fig. 3e). Furthermore, circulating SPINT1 concentra-
tions at 24–34 weeks’ gestation was also correlated with uterine
artery Doppler velocities (Fig. 3f) and placental surface area
(Fig. 3g) measured by ultrasound at 22–24 weeks, that is,
ultrasound findings from the mid-trimester (suggesting the early
development of placental insufficiency) which preceded blood
sampling by several weeks.
Thus, we validated that circulating SPINT1 concentrations are
correlated with several clinical parameters that are associated with
placental insufficiency in a high-risk cohort from a different
country than the cohort we used to discover the association.
Circulating SPINT1 in severe fetal growth restriction. Most
cases of preterm fetal growth restriction requiring iatrogenic birth
remote from term are affected by severe placental insufficiency. In
cases of preterm fetal growth restriction (delivered < 34 weeks’
gestation), placental SPINT1 mRNA and protein expression
(Fig. 4a, b) were significantly reduced compared with controls
(patient characteristics shown in Supplementary Table 11).
Fig. 1 Plasma concentrations of SPINT1 were significantly reduced preceding the birth of a small for gestational age (SGA) infant. Scatter plots and
receiver operator curves of SPINT1 in two cohorts (a, b; cohort 1, c, d; cohort 2) demonstrate SPINT1 concentrations were significantly reduced (a, p=
2.70 × 10−13, b, p= 5.24 × 10−8) in the circulation of women at 36 weeks who subsequently delivered an SGA infant (birthweight < 10th centile). Plasma
PlGF concentrations at 36 weeks were also significantly reduced in cohort 2 (e, f, p= 3.81 × 10−3). A comparison between receiver operator curves for
SPINT1 and PlGF indicated SPINT1 had improved area under the receiver operator curve (g). In a case–control sample set selected from cohort 1, SPINT1
was significantly reduced at 28 weeks’ gestation (h, p= 3.59 × 10−9). Cases where SPINT1 were low at 28 weeks’ gestation tended to remain low by
36 weeks’ gestation (i). Cohort 1, n= 891 controls, n= 106 SGA. Cohort 2 n= 893 controls, n= 105 SGA, Case control at 28 weeks, n= 100 controls, n=
84 SGA. **p < 0.01, ****p < 0.0001, groups compared using two-tailed Mann–Whitney U tests. AUC—area under the ROC curve, with 95% confidence
intervals given in brackets. Data depicted for a, c and e are mean ± s.e.m. Source data included as a Source Data file.
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Circulating plasma SPINT1 concentrations were also reduced
among pregnancies complicated by preterm fetal growth restric-
tion compared with healthy pregnancies (patient characteristics
given in Supplementary Table 12), with an area under the receiver
operated curve of 0.948 (Fig. 4c, d). Changes in serum from the
same cohort were far less pronounced (Supplementary Fig. 4d),
suggesting SPINT1 should be measured in plasma, not serum.
SPINT1 in a mouse model of fetal growth restriction. We
induced placental insufficiency and fetal growth restriction using
a mouse model of late-term maternal hypoxic exposure17. This
led to fetuses with 25% reduced fetal weight (Supplementary Fig.
6). Placental Spint1 mRNA and SPINT1 protein expression were
significantly reduced among cases where maternal hypoxia-
induced fetal growth restriction (Fig. 4e, f). These data are con-
sistent with the possibility that SPINT1 may play an important
biological role in normal placental function.
Discussion
By screening proteins that are highly expressed on the surface of
the placenta we have identified a strong association between low
circulating concentrations of SPINT1 at 36 weeks’ gestation and
placental insufficiency.
We have robustly proven the association between circulating
SPINT1, and low birthweight given we validated the association
in cohort 2, a sample set that is independent of the cohort (cohort
1) we used to discover SPINT1. Importantly, we externally vali-
dated this association in a cohort from Manchester UK, an
independent cohort of samples from another country. We also
showed circulating levels were lower in a further cohort of
pregnancies complicated by preterm fetal growth restriction (a
severe form of placental insufficiency).
Furthermore, we have generated tests using our validation
cohort that may have clinical applicability, especially given all
existing tests perform modestly for detecting fetal growth
restriction. A low SPINT1 identified a population with a sig-
nificantly increased risk of delivering a neonate with a low
birthweight. The positive predictive values were encouraging and
potentially clinically acceptable as they ranged between 10 and
38%, depending on the birthweight centile cut-off. Many of these
infants would have also been small in utero, and at increased risk
of placental insufficiency and stillbirth while they remained
undelivered.
Using cohort 2, we also propose a 4-tier risk model that
identifies cohorts at high or low risk of birthing a neonate of low
birthweight centile where presumably, it also identifies unborn
fetuses at low weights and at increased risk of stillbirth. This
model is able to assign a level of risk that is different from the
baseline prevalence in just under half of the population who have
the test (tiers 1, 3, and 4). This 4-tier model requires validation in
an independent cohort.
If validated however, we posit that our 4-tier model has pro-
mising clinical value, given current approaches to detect growth
restricted fetuses are so limited and an intervention exists that
does not cause harm in the cases of false positives (induction of
labor). Those in tier 1 may be offered a planned birth at term to
reduce the risk of stillbirth and possibly perinatal morbidity.
Alternately, it could be used to reassure a large number of women
that their risk of having a growth restricted fetus at term is halved
(tier 3) or extremely low (tier 4). As such, awaiting spontaneous
labor beyond their due date may be a safe decision compared with
the general population who were not tested. The test does not
help triage risk for those in tier 2, which is a little over half of the
population.
There is no gold standard clinical definition of placental
insufficiency, which makes it challenging to develop a screening
test that will be universally accepted. Thus, we examined the
association between SPINT1 and many indicators of placental
insufficiency. We found low SPINT1 concentrations at 36 weeks’
Table 1 Diagnostic performance of circulating SPINT1 concentrations at 35+0–37+0 weeks’ gestation to identify fetuses born at
varying low birthweight cut-offs.
Birthweight < 3rd
centile
Birthweight < 5th
centile
Birthweight < 10th
centile
Birthweight < 20th
centile
Birthweight < 5th centile
and nursery admission
Positive
predictive value
10.2% (5.2–17.5) 16.1% (9.8–24.2) 22.6% (15.3–31.3) 37.9% (29.3–47.1) 4.8% (1.6–10.8)
Negative
predictive value
98.3% (97.2–99.1) 96.5% (95.1–97.6) 90.9% (88.9–92.8) 78.4% (75.5– 81.1) 99.7% (99.0–99.9)
Risk ratio (95% CI) 6.04 (2.85–12.82) 4.59 (2.66–7.93) 2.50 (1.68–3.71) 1.75 (1.35–2.27) 14.2 (3.44–58.47)
Sensitivity 42.3% (23.4–63.1) 36.7% (23.4–51.7) 24.5% (16.7–33.8) 19.9% (15.0–25.6) 62.5% (24.5–91.5)
Specificity 90.0% (88.0–91.8) 90.1% (88.0–91.9) 90.0% (87.9– 91.9) 89.9% (87.5–91.9) 89.9% (87.9–91.7)
This data was derived from Cohort 2, our validation cohort and calculated from the 998 participants where there was a SPINT1 readout from the assay (a further four samples did not detect SPINT1 and
were excluded).
Table 2 Four-tier risk model for delivery of neonates with different low birthweight cut-offs.
TIER SPINT1
MoM
cut-off
% (no)
within tier
Birthweight <
3rd centile
Birthweight <
5th centile
Birthweight <
10th centile
Birthweight <
20th centile
Birthweight < 5th
centile and nursery
admission
1: High risk <0.63 7.1% (71) 14.1% 19.7% 28.2% 46.5% 7.0%
2: Normal risk 0.63–1.1 57.0% (569) 2.3% 4.4% 11.8% 27.4% 0.4%
3: Lower risk 1.1–1.6 26.8% (268) 1.1% 3.0% 6.3% 14.9% 0.4%
4: Lowest risk >1.6 9.1% (91) 0.0% 1.1% 1.1% 6.6% 0.0%
The data were derived from cohort 2 (validation cohort). Risk model developed by selecting different thresholds of circulating levels SPINT1 MoM concentrations measured among pregnant women at
35+0–37+0 weeks’ gestation.
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gestation (1) has a step-wise association with SGA birthweight
centiles <10th, 5th, 3rd centiles, (2) is associated with reduced
neonatal lean mass at birth, (3) has a negative correlation with
uterine artery blood flow resistance measured at 36 weeks’
gestation, and (4) is correlated with placental weight. Also, (5)
SPINT1 levels are low in the placentas and the maternal circu-
lation from pregnancies complicated by preterm fetal growth
restriction (a severe form of placental insufficiency) and (6) in a
mouse model of fetal growth restriction. Thus, our data suggests
low circulating SPINT1 levels may reflect genuine placental
insufficiency, not just low birthweight.
To induce fetal growth restriction in our murine model we
induced maternal hypoxia. Our model is limited because when
there is fetal growth restriction in humans the mother is not
hypoxic, meaning our in vivo model does not entirely mimic the
pathophysiology of this disease. Nevertheless, this model is still
likely to induce fetal hypoxia (which does occur with fetal growth
restriction) and is therefore still relevant to human disease.
SPINT1 is a membrane bound cell surface protease first
identified for its capacity to inhibit hepatocyte growth factor
activator. Target cell surface proteases for SPINT1 include
matriptase, prostasin and hepsin. Notably, Spint1 deficiency in
genetic mouse knockout studies causes embryonic lethality with
severe placental abnormalities and a failure of labyrinth devel-
opment18. Although animal studies suggest a pertinent role for
SPINT1 in normal placental development, limited data has been
reported on the biological role of SPINT1 in human placenta. Our
interest in SPINT1 stemmed from the fact that of all tissues in the
body, it appears to be most highly expressed in placenta. Now we
have made the primary observation that low SPINT1 is associated
with placental insufficiency, it may be worthwhile for future
studies to elucidate molecular mechanisms and to tease out
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whether it is a bystander, or driver of placental disease. If the
latter, then druggable therapeutic targets could be discovered
within the SPINT1 regulatory pathway.
While a number of biomarkers have been identified as having a
strong association with preeclampsia (another pregnancy com-
plication associated with placental disease)19, circulating markers
specific for placental insufficiency have been harder to come by,
especially during the third trimester. Low circulating PIGF is
perhaps the most promising and certainly the most avidly
investigated to date20–22. Our study suggests circulating SPINT1
around 36 weeks’ gestation may have a considerably stronger
association with several indicators of placental insufficiency
than PIGF.
There will need to be further development of SPINT1 before it
can be applied to the clinic, including the generation of a com-
mercial grade ELISA and further validation in other cohorts.
Given circulating SPINT1 may reflect true placental insuffi-
ciency, it has the potential to be applied in a variety of other
clinical situations to reduce the stillbirth risk, such as monitoring
fetuses with co-existing obstetric complications, or those that are
post term. Furthermore, combining SPINT1 with other bio-
markers (including those that are yet to be reported) or with
ultrasound findings at different gestations may yield a highly
accurate diagnostic test of fetal growth restriction and placental
insufficiency.
A clinical test that helps health care providers better detect fetal
growth restriction could reduce the burden of preventable still-
births, a devastating outcome that prematurely ends around 3
million pregnancies globally each year.
Methods
Discovery of new biomarkers of placental insufficiency. To identify new bio-
markers of placental insufficiency we performed the FLAG study, a prospective
collection of blood samples from pregnant women at 28 (27+0–29+0) and 36
(35+0–37+0 days) weeks gestation from a tertiary referral hospital in Melbourne
Australia. This study was approved by the Mercy Health Research Ethics Com-
mittee (Ethics Approval Number R14/12) and written informed consent was
obtained from all participants.
We divided the cohort approximately in half to discover, and then subsequently
validate markers. Samples from the first 1001 consecutively recruited participants
constituted cohort 1 and those from the second 1002 consecutively recruited
participants constituted cohort 2.
We also recruited a subcohort of 347 nulliparous women in the FLAG study to
undergo more intensive studies. They had ultrasound assessments at 36 weeks’
gestation to measure blood flow resistance in the uterine, umbilical and the fetal
middle cerebral arteries. Where possible, we measured neonatal body composition
(lean body mass and fat mass) within 4 days of birth by performing air
displacement plethysmography studies using a PEAPOD device. Further methods
for the FLAG study are detailed in the Supplementary Information.
We initially screened 22 circulating proteins in a nested case (neonates born
small for gestational age, SGA, birthweight <10th centile) control (neonates born
>10th centile) set selected from cohort 1. We selected proteins that are highly
expressed in placenta relative to other tissues by referencing two bioinformatic
databases and choosing proteins that were (1) highly expressed at the mRNA level
in placenta relative to all other human tissues (using BioGPS) and (2) its protein
product is abundantly expressed on the membrane surface of the placenta (using
Protein Atlas).
The proteins screened where circulating concentrations were different among
cases of SGA compared to controls were re-assayed in a new batch assay run
performed on all samples from cohort 1. Those that remained significantly
associated with SGA were then assayed in cohort 2. Further methods on how the
proteins were measured are detailed in the Supplementary Information.
Developing diagnostic tests for placental insufficiency. Using the data from
cohort 2 (the validation run of markers discovered in cohort 1), we examined the
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diagnostic performance of potential markers, either alone or in combination, to
predict neonates born at birthweight centiles; <20th, <10th, <5th, and <3rd; and
birthweight <5th centile but also required nursery admission. We set the specificity
at around 90%, which equates to a 10% screen positive rate.
We found SPINT1 performed the best, and no other markers added to its
performance. Therefore, we focused on SPINT1. To adjust for the fact that the
research ELISA we used exhibited variability in reporting the absolute SPINT1
concentrations between the batch runs for cohorts 1 and 2, we expressed SPINT1
results as multiples of the median (MoMs).
We used cohort 2 (our validation cohort) to develop a 4-tier risk model (that
divides the cohort into different levels of SPINT1 MoM concentrations in the
circulation at 36 weeks’ gestation) that can stratify the entire population into 4
levels of risk of birthing a neonate at a low birthweight.
Further methods describing the statistical analyses are detailed in the
Supplementary Information.
Validation in the MAViS cohort. To validate the observation that SPINT1 is
associated with placental insufficiency we measured SPINT1 in plasma samples
obtained from a high-risk cohort in the United Kingdom, the Manchester
Antenatal Vascular Service (The MAViS clinic, clinical characteristics shown in
Supplementary Table 3 and inclusion/exclusion criteria provided in the Supple-
mentary Methods). Women gave written informed consent to donate samples for
future research studies. The study was approved by the NRES Committee North
West 11/NW/0426. Women with current hypertension or a hypertensive disorder
in a prior pregnancy are referred to the MAViS research clinic from early preg-
nancy and followed longitudinally with blood samples taken at ~4-week intervals.
Such pregnancies are known to have an elevated risk of preeclampsia, SGA or fetal
growth restriction. Uterine artery Doppler was performed at each visit and pla-
cental size measured at 22–24 weeks gestation by measuring the two widest per-
pendicular diameters of the placenta. A case-cohort of 291 participants were
recruited between October 2011 and December 2016, where a plasma sample was
obtained between 24 and 34 weeks and complete outcome data were available were
analysed in the current study. The set of 291 participants were selected from a
biobank of 518 participants. The clinical characteristics are shown in Supple-
mentary Table 5. The table also shows the clinical characteristics of the case-cohort
(n= 291) selected for this study were no different to the whole consecutive MAViS
cohort (n= 518). Women attending the MAViS clinic underwent an ultrasound
based ‘placental screen’ at 22–24 weeks gestation as per local guidelines. This
consisted of ultrasound assessment of fetal size (Fetal biometry), 2D placental
biometry (three dimensions at their widest points), liquor volume (amniotic fluid
index and maximum vertical pool depth), uterine artery and umbilical artery
Dopplers. Uterine artery was measured by a specialist team of research staff
(midwife ultrasound practitioners and Doctors) using standard techniques and an
average of triplicate measurements recorded. Placental surface area was calculated
by multiplying the two largest measurements from the placenta (width × diameter).
Measurements obtained at the same time as the last blood sample are included in
the analysis for this study. SPINT1 is expressed a MoMs to correct for gestational
changes in SPINT1 in the UK cohort.
Levels of SPINT1 in preterm growth restriction. We further investigated SPINT1
by correlating circulating levels with several other clinical indicators of placental
insufficiency using data obtained from our subcohort. We also measured circu-
lating SPINT1 concentrations and placental expression in a separate cohort with
fetal growth restriction who delivered <34 weeks gestation and in a mouse model of
fetal growth restriction17.
Methods are further described in the Supplementary Information.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The source data underlying all figures and supplementary figure are provided as a Source
Data file.
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